Published in
Esmo Open, Esmo Open, 6(7), p. 100639, 2022
DOI: 10.1016/j.esmoop.2022.100639
Links
Tools
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
Journal article published in 2022 by
E. Garralda 
,
A. Sukari,
N. J. Lakhani,
A. Patnaik,
Y. Lou,
S.-A. Im,
T. Golan,
R. Geva,
M. Wermke,
M. de Miguel,
J. Palcza,
S. Jha,
M. Chaney,
A. K. Abraham,
J. Healy
and other authors.
,
A. Sukari,
N. J. Lakhani,
A. Patnaik,
Y. Lou,
S.-A. Im,
T. Golan,
R. Geva,
M. Wermke,
M. de Miguel,
J. Palcza,
S. Jha,
M. Chaney,
A. K. Abraham,
J. Healy
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Data provided by 